0001437749-21-001530.txt : 20210129 0001437749-21-001530.hdr.sgml : 20210129 20210129091528 ACCESSION NUMBER: 0001437749-21-001530 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20210129 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210129 DATE AS OF CHANGE: 20210129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474671999 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37758 FILM NUMBER: 21568419 BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 8-K 1 mbrx20210128_8k.htm FORM 8-K mbrx20210128_8k.htm
false 0001659617 0001659617 2021-01-29 2021-01-29
--12-31
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 29, 2021
 
mbrx20210128_8kimg001.jpg
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification
No.)
 
5300 Memorial Drive, Suite 950, Houston ,TX 77007
(Address of principal executive offices and zip code)
 
(713) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC
 
 

 
Item 3.03. Material Modifications of Rights of Security Holders.
 
To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 herein is incorporated by reference into this Item 3.03.
 
 
Item 5.03     Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
At the Moleculin Biotech, Inc. (the “Company”) annual meeting of stockholders completed on June 15, 2020, the stockholders of the Company approved an amendment to the Company’s amended and restated certificate of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-8, with such ratio to be determined in the discretion of the Company’s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors in its sole discretion prior to the one-year anniversary of the annual meeting.
 
Pursuant to such authority granted by the Company’s stockholders, the Company’s board of directors approved a one-for-six(1:6) reverse stock split (the “Reverse Stock Split”) of the Company’s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 5:00 p.m. Eastern Time on January 29, 2021 (the “Effective Time”). The Amendment provides that, at the Effective Time, every six shares of the Company’s issued and outstanding common stock will automatically be combined into one issued and outstanding share of common stock, without any change in par value per share, which will remain $0.001.
 
As a result of the Reverse Stock Split, the number of shares of common stock outstanding will be reduced from approximately 72 million shares to approximately 12 million shares, and the number of authorized shares of common stock will remain at 100 million shares. As a result of the Reverse Stock Split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards and warrants, which will result in a proportional decrease in the number of shares of the Company’s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company’s equity compensation plan immediately prior to the Effective Time will be reduced proportionately.
 
No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share will be entitled to the rounding up of the fractional share to the nearest whole number. The Reverse Stock Split will be effective at 5:00 p.m., Eastern Time, on January 29, 2021, and the Company’s common stock is expected to begin trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market at the open of the markets on February 1, 2021. The trading symbol for the common stock will remain “MBRX.” The Company’s post-Reverse Stock Split common stock has a new CUSIP number (CUSIP No. 60855D200), but the par value and other terms of the common stock are not affected by the Reverse Stock Split.
 
The summary of the of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
 
 

 
Item 8.01
Other Events
 
On January 29, 2021, the Company issued a press release to announce that today announced that it filed a certificate of amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of its common stock. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)     Exhibits.
 
Exhibit No.
Description
 
104
Cover page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MOLECULIN BIOTECH, INC.
 
 
 
Date: January 29, 2021
 
By: /s/ Jonathan P. Foster
Jonathan P. Foster
Chief Financial Officer
 
 
EX-3.1 2 ex_223281.htm EXHIBIT 3.1 ex_223281.htm

Exhibit 3.1

STATE OF DELAWARE

CERTIFICATE OF AMENDMENT

OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

MOLECULIN BIOTECH, INC.

 

Moleculin Biotech, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”) for the purpose of amending its Amended and Restated Certificate of Incorporation in accordance with the General Corporation Law of the State of Delaware, does hereby make and execute this Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, and does hereby certify that:

 

1.      The Board of Directors of the Corporation (the “Board”), acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending Article 4.1 of its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), so that effective upon the effective time of this Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware, six (6) shares of the Corporation’s common stock, par value $0.001 per share (hereinafter the “Common Stock”), issued and outstanding shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one share of Common Stock without increasing or decreasing the par value of each share of Common Stock (the “Reverse Stock Split”) and without increasing or decreasing the authorized number of shares of Common Stock or the Corporation’s preferred stock, par value $0.001 per share (hereinafter the “Preferred Stock”); provided, however, no fractional shares of Common Stock shall be issued in connection with the Reverse Stock Split, and instead, the Corporation shall issue one full share of post-Reverse Stock Split Common Stock to any stockholder who would have been entitled to receive a fractional share of Common Stock as a result of the Reverse Stock Split. The Reverse Stock Split shall occur whether or not the certificates representing such shares of Common Stock are surrendered to the Corporation or its transfer agent.

 

2.      Thereafter, pursuant to a resolution of the Board, a meeting of the stockholders of the Corporation was duly called and held upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the foregoing amendment.

 

3.      The foregoing amendment has been duly adopted in accordance with the provisions of Section 242 of the General Corporation law of the State of Delaware by the vote of a majority of each class of outstanding stock of the Corporation entitled to vote thereon.

 

4.      This amendment shall be effective as of 5:00 p.m., Eastern Time, on January 29, 2021.

 

IN WITNESS WHEREOF, I have signed this Certificate this 28th day of January, 2021.

 

 

 

/s/ Jonathan P. Foster          

Jonathan P. Foster

Chief Financial Officer

 

 
EX-99.1 3 ex_223282.htm EXHIBIT 99.1 ex_223282.htm

Exhibit 99.1

ex_223282img001.jpg

 

Moleculin Announces Reverse Stock Split

 

 

HOUSTON, January 29, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it filed a certificate of amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of its common stock. The reverse stock split will take effect at 5:00 pm (Eastern Time) on January 29, 2021, and the Company’s common stock will open for trading on The Nasdaq Capital Market on February 1, 2021 on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D200.

 

As a result of the reverse stock split, every six shares of the Company’s common stock issued and outstanding prior to the opening of trading on February 1, 2021 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.001. No fractional shares will be issued as a result of the reverse stock split. Stockholders of record who would otherwise be entitled to receive a fractional share will be entitled to the rounding up of the fractional share to the nearest whole number.

 

As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 72.0 million shares to approximately 12.0 million shares, and the number of authorized shares of common stock will remain at 100 million shares. As a result of the reverse stock split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards and warrants, which will result in a proportional decrease in the number of shares of the Company’s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company’s equity compensation plan immediately prior to the reverse stock split will be reduced proportionately.

 

 

 

About Moleculin Biotech, Inc.

 

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

 

For more information about the Company, please visit http://www.moleculin.com.

Forward-Looking Statements 

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of the reverse stock split. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.  Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

Contacts

James Salierno / Carol Ruth

The Ruth Group

973-255-8361 / 917-859-0214

jsalierno@theruthgroup.com

cruth@theruthgroup.com

 
EX-101.SCH 4 mbrx-20210129.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 5 mbrx-20210129_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 mbrx-20210129_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Current Fiscal Year End Date Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Entity, Ex Transition Period Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 7 mbrx-20210129_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 ex_223282img001.jpg begin 644 ex_223282img001.jpg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mbrx20210128_8kimg001.jpg begin 644 mbrx20210128_8kimg001.jpg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end XML 10 mbrx20210128_8k_htm.xml IDEA: XBRL DOCUMENT 0001659617 2021-01-29 2021-01-29 false 0001659617 --12-31 8-K 2021-01-29 MOLECULIN BIOTECH, INC. DE 001-37758 47-4671997 5300 Memorial Drive Suite 950 Houston TX 77007 713 300-5160 false false false false true true Common Stock MBRX NASDAQ XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document And Entity Information
Jan. 29, 2021
Document Information [Line Items]  
Entity, Registrant Name MOLECULIN BIOTECH, INC.
Current Fiscal Year End Date --12-31
Document, Type 8-K
Document, Period End Date Jan. 29, 2021
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37758
Entity, Tax Identification Number 47-4671997
Entity, Address, Address Line One 5300 Memorial Drive
Entity, Address, Address Line Two Suite 950
Entity, Address, City or Town Houston
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 77007
City Area Code 713
Local Phone Number 300-5160
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company true
Entity, Ex Transition Period true
Title of 12(b) Security Common Stock
Trading Symbol MBRX
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0001659617
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .Y)/5('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #N23U2]]HU@.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NLD$:%&7"X@32$A, G&+'&^+:-HH,6KW]K1EZX3@ 3C&_O/Y ML^0:H\8NT7/J(B7VE*^&T+198]R( W/4 !D/%&PNQT0[-G=="I;'9]I#M/AA M]P2JJFX@$%MGV<($+.)"%*9VJ#&1Y2Z=\ X7?/Q,S0QS"-10H)8SR%*",-/$ M>!R:&BZ "<:40OXND%N(<_5/[-P!<4H.V2^ION_+?C7GQATDO#T]OLSK%K[- M;%ND\5?VFH^1-N(\^75U=[]]$$952A:5+-1Z6ZVUO-;J]GUR_>%W$0Z=\SO_ MCXW/@J:&7W=AO@!02P,$% @ [DD]4IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #N23U2] D>UWP$ A$@ & 'AL+W=O?0L-3.Q."+2X..X090DA#-Q<:V&XOTP=A"]#$EEA)7N#; M]\B 36?-,9V^X*O^^DE'YW^$>QNEW\V*0334R:)$SO M[GBL-K?UQ,-5XU<)1()ET8H231?W-8&_L<[ M&K@&V1N_";XQ)^?$#66NU+N[&$>W-<\1\9B'UDDP.'SC0Q['3@DXOAY$:WF? MKN'I^5'](1L\#&;.#!^J^(N([.JV=E,C$5^P-+9O:O/(#P-J.[U0Q2;[)9O] MNZUVC82IL2HY- :"1,C]D6T/$W'2@+;.-*"'!C3CWG>44=XSR_H]K39$N[=! MS9UD0\U: YR0+BI3J^&I@':V?Z_"%";9DH&,R$A:87=D+/?1AEGK-2QTXEYM MA ?!N[T@/2/X"Y/7A':O"/6H_^_F#6#+ 6D.2#.]9A7@"17YZPG>(F/+$_,W MTD7Y]&P\]/XQ=R-WZ=C8:/ M5V3\,KQ&$%LY8@M5'J9:NUEX$"9D,?F#,PWAB@@$O9035ZO7?5IO8N%IYUQM M5.D8GBLRVZU+2?#V-_5/"$4GI^A<2#'A6J@(G1I_'R&(-SGBS46(#R+FY"5-YER7 MD> BGN?7FT'0OD& NCE0]R*@&=N2<021%0L1[G/_/!XNV0KJK4[@=[L!PN=[ MA6]Z%Q$.HDAS8_(3DEG3JRP-985FN^EYY)DG2@O(\7L-]0IC/?%X_W^PSC:J ME!77G*8"EF^W[6&$AF2%$:?-S; MLQ@.8*]X'@47"/PF!E)4!Q_W]"?E:N9DI23F;A4BD)OUMM]!UWM1$GS:UT.8'@X)EFT 9UQ&7)/7Q>),_'"]*C):6#_%;?H[LK$Q*9!5 5;( M5@(6?D\O\_M1PO72!?1GD+ KM]K63.Y*V7!%JU,4[60W?YG1C[9D!AMM([*: MOM^UE7+A@4]^/CK$#TPA632W[V;U*%T,M@ M>C_X%6,JO)WBMCR #(RR+'R(V;*4!1>H3+O"U.EE&_TAT&@H.&.P@RWYQ,M7 M$:[EP6ZZT^YV_-)2W#CYP^\^GCPSE^>&Q'P!:MYU -.O]]\C]A=6K;-O '-E MK4JRTQ5GX%;N!7B^4,H>+]QGA?RK4/\?4$L#!!0 ( .Y)/5*#J:4#U $ M #(& - >&PO+]*V-!^TQCG.+HH6M9;QWPN@^#E&3IZ73/%!>:%ID>U(/"GE1F MT)C3$V5%UAB],Z]I)'PI5T N7.;T Y>B=&*NY4K(*=)I("HCC2/HK4!.D\#T MSS&=1!1<+CI*:.,"R6*'^%LNY3\E5M1[**3<#*8T$D5F.2(X_>#!7#R3+U)D MB<^3]0Y;QZ"V-@E=J2*3T 0[3K1=^**Q+"01C?)!+7AK M-)\]K".6P,M6(.53V,*OS97VV)"X%Q_KL TD3'4-O:$EC#(1!/VC6M0^R-[] MD2RQXF+P_>!GHV?\;3 (CPX:,OZ[Z]R"!L?ET;0_ M^O_R*O^.8[;-/E_G;@ M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/ M['X 4$L#!!0 ( .Y)/5(ZJJ+G0 $ #P" / >&PO=V]R:V)O;VLN M>&ULC5%=:\,P#/PKQC]@20SH\0RVT+E6J:'3"T4\4V#C-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&% MGN5"6&-,W&_T_$8T'D&6A^[ ](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_ M,5)=8P5+J@X> @\Y1G"=P) :;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H. MKEGD7F08YRB#N+*#\%&MA1H#V#:;7-Y-;2>C@W(-@[^&5 MC!W-CQ]W]P-02P,$% @ [DD]4B0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C M,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI M160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=% MKLWC":[?#'!X=/X!4$L#!!0 ( .Y)/5)ED'F2&0$ ,\# 3 6T-O M;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^ MDV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT M(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W" MS&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE M8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F M"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 M ( .Y)/5+T"1[7? 0 "$2 8 " @0X( !X;"]W;W)K M&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " #N23U299!YDAD! #/ P $P @ 'Z$0 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" !$$P ! end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mbrx.com/20210129/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mbrx20210128_8k.htm ex_223281.htm ex_223282.htm mbrx-20210129.xsd mbrx-20210129_def.xml mbrx-20210129_lab.xml mbrx-20210129_pre.xml mbrx20210128_8kimg001.jpg http://xbrl.sec.gov/dei/2020-01-31 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mbrx20210128_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "mbrx-20210129_def.xml" ] }, "inline": { "local": [ "mbrx20210128_8k.htm" ] }, "labelLink": { "local": [ "mbrx-20210129_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mbrx-20210129_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mbrx-20210129.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mbrx", "nsuri": "http://www.mbrx.com/20210129", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mbrx20210128_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.mbrx.com/20210129/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mbrx20210128_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity, Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity, Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210129/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 18 0001437749-21-001530-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-001530-xbrl.zip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